title: Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
authors.affiliation: Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece. vathyros@gmail.com.
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.forename: Niki
authors.initials: N
authors.lastname: Katsiki
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Tentolouris
mesh_terms: D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000379:methods; D048909:Diabetes Complications / Q000097:blood / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide / Q000627:therapeutic use*; D016896:Treatment Outcome; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; D000067757:Glucagon-Like Peptide-1 Receptor
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor